VERA THERAPEUTICS, INC. |
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 37.91 USD | -0.16% |
|
-9.68% | +146.29% |
| May. 17 | Vera Therapeutics Insider Sold Shares Worth $1,304,435, According to a Recent SEC Filing | MT |
| May. 10 | Wedbush Adjusts Vera Therapeutics' PT to $32 From $34, Keeps Neutral Rating | MT |
Presenter SpeechAnupam Rama (Analysts)All right. Let's go ahead and get started. Welcome to th...
This article is reserved for subscribers
Signed up already?
Log InNot subscribed yet?
Subscribe
Vera Therapeutics, Inc. is a late-stage biotechnology company. The Company is focused on developing and commercializing transformative treatments for patients with serious immunological diseases. Its product candidate, atacicept, is a self-administered fusion protein that blocks both a B lymphocyte stimulator (BLyS) and a proliferation-inducing ligand (APRIL) which stimulates B cells and plasma cells to produce autoantibodies contributing to certain autoimmune diseases. The Company is also engaged in developing MAU868, a monoclonal antibody designed to neutralize infection with BK Virus, a polyomavirus that can have devastating consequences in certain settings such as kidney transplants. The Company is conducting a randomized, double-blind, placebo-controlled Phase 3 clinical trial in IgAN, which it refers to as ORIGIN 3, and completing the open label extension of its Phase 2b clinical trial in IgAN, which it refers to as ORIGIN 2b.
Calendar
Related indices
Sell
Buy
Mean consensus
BUY
Number of Analysts
10
Last Close Price
37.97
USD
Average target price
56.7
USD
Spread / Average Target
+49.33%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| +146.29% | 2.08B | |
| +63.86% | 62.59B | |
| -1.27% | 41.18B | |
| +44.76% | 40.29B | |
| -8.29% | 27.9B | |
| +12.95% | 26.21B | |
| -21.61% | 19.09B | |
| +5.34% | 13.08B | |
| +25.43% | 12.26B | |
| +28.41% | 12.05B |
- Stock Market
- Equities
- VERA Stock
- News Vera Therapeutics, Inc.
- Transcript : Vera Therapeutics, Inc. Presents at 41st Annual J.P. Morgan Healthcare Conference, Jan-10-2023 01
